Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 444

Dr Tait Shanafelt - Standford University, Stanford, USA

Dr Tait Shanafelt gives a press conference at ASH 2018 on the findings of the E1912 which show the combination of ibrutinib and rituximab to be superior to FCR chemoimmunotherapy for younger patients with previously untreated CLL.

Watch his interview with ecancer here.

Read more about this work here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation